Polysaccharide from Lentinus edodes combined with oxaliplatin possesses the synergy and attenuation effect in hepatocellular carcinoma

Cancer Letters

Volumn 377, Issue 2, 2016, Pages 117-125

  Zhang, Yu ^a   Li, Qiang ^a   Wang, Junfeng ^b   Cheng, Fang ^b   Huang, Xiao ^a   Cheng, Yao ^a   Wang, Kaiping ^b  

^a UNION HOSPITAL   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Hepatocellular carcinoma; Lentinan; Oxaliplatin; Polysaccharide

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXALIPLATIN; POLYSACCHARIDE; STAT3 PROTEIN; SURVIVIN; TUMOR MARKER; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; LENTINAN; PLATINUM COMPLEX; REPRESSOR PROTEIN; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DIARRHEA; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SAFETY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTINULA EDODES; LIVER CELL CARCINOMA; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HEP-G2 CELL LINE; LIVER MITOCHONDRION; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HEP G2 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LENTINAN; LIVER NEOPLASMS; MALE; MICE, INBRED BALB C; MITOCHONDRIA, LIVER; NF-KAPPA B; ORGANOPLATINUM COMPOUNDS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; TUMOR BURDEN;

EID: 84964938503     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.04.037     Document Type: Article

References (49)

1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin 2015, 65:87-108.
2. Graf D., Vallbohmer D., Knoefel W.T., Kropil P., Antoch G., Sagir A., et al. Multimodal treatment of hepatocellular carcinoma. Eur. J. Intern. Med 2014, 25:430-437.
3. Nagasue N., Kohno H., Chang Y.C., Taniura H., Yamanoi A., Uchida M., et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann. Surg 1993, 217:375-384.
4. Zhou Y., Sui C., Li B., Yin Z., Tan Y., Yang J., et al. Repeat hepatectomy for recurrent hepatocellular carcinoma: a local experience and a systematic review. World J. Surg. Oncol 2010, 8:55.
5. Nagasue N., Kohno H., Tachibana M., Yamanoi A., Ohmori H., El-Assal O.N. Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis. Ann. Surg 1999, 229:84-90.
6. Carr B.I. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004, 127:S218-S224.
7. Galluzzi L., Senovilla L., Vitale I., Michels J., Martins I., Kepp O., et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31:1869-1883.
8. Hochster H., Chachoua A., Speyer J., Escalon J., Zeleniuch-Jacquotte A., Muggia F. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J. Clin. Oncol 2003, 21:2703-2707.
9. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol 1996, 52:1855-1865.
10. Culy C.R., Clemett D., Wiseman L.R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000, 60:895-924.
11. Cunningham D., Okines A.F., Ashley S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med 2010, 362:858-859.
12. Yen Y., Lim D.W., Chung V., Morgan R.J., Leong L.A., Shibata S.I., et al. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am. J. Clin. Oncol 2008, 31:317-322.
13. Yen Y., Doroshow J., Leong L., Lim D., Wagman L., Morgan R., et al. Phase II study of oxaliplatin in patients with unresectable, metastatic or recurrent hepatocellular cancer. ASCO Annual Meeting Proceedings 2004, 4169.
14. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol 2000, 18:2938-2947.
15. Xu X., Yan H., Tang J., Chen J., Zhang X. Polysaccharides in Lentinus edodes: isolation, structure, immunomodulating activity and future prospective. Crit. Rev. Food Sci. Nutr 2014, 54:474-487.
16. Oba K., Kobayashi M., Matsui T., Kodera Y., Sakamoto J. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res 2009, 29:2739-2745.
17. Nishitani Y., Zhang L., Yoshida M., Azuma T., Kanazawa K., Hashimoto T., et al. Intestinal anti-inflammatory activity of lentinan: influence on IL-8 and TNFR1 expression in intestinal epithelial cells. PLoS ONE 2013, 8:e62441.
18. Xu X., Zhang X. Lentinula edodes-derived polysaccharide alters the spatial structure of gut microbiota in mice. PLoS ONE 2015, 10:e0115037.
19. Zhang Y., Li Q., Shu Y.M., Wang H.J., Zheng Z.M., Wang J.L., et al. Induction of apoptosis in S180 tumour bearing mice by polysaccharide from Lentinus edodes via mitochondria apoptotic pathway. J. Funct. Foods 2015, 15:151-159.
20. Wang K.P., Zhang Q.L., Liu Y., Wang J., Cheng Y., Zhang Y. Structure and inducing tumor cell apoptosis activity of polysaccharides isolated from Lentinus edodes. J. Agric. Food Chem 2013, 61:9849-9858.
21. Wang K.-P., Wang J., Li Q., Zhang Q.-L., You R.-X., Cheng Y., et al. Structural differences and conformational characterization of five bioactive polysaccharides from Lentinus edodes. Food Res. Int 2014, 62:223-232.
22. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
23. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul 1984, 22:27-55.
24. Facchini J.M., Alves E.P., Aguilera C., Gern R.M., Silveira M.L., Wisbeck E., et al. Antitumor activity of Pleurotus ostreatus polysaccharide fractions on Ehrlich tumor and Sarcoma 180. Int. J. Biol. Macromol 2014, 68:72-77.
25. Unursaikhan S., Xu X., Zeng F., Zhang L. Antitumor activities of O-sulfonated derivatives of (1→3)-alpha-D-glucan from different Lentinus edodes. Biosci. Biotechnol. Biochem 2006, 70:38-46.
26. Lai K.-C., Liu C.-J., Lin T.-J., Mar A.-C., Wang H.-H., Chen C.-W., et al. Blocking TNF-α inhibits angiogenesis and growth of IFIT2-depleted metastatic oral squamous cell carcinoma cells. Cancer Lett 2016, 370:207-215.
27. Gibson R.J., Bowen J.M., Inglis M.R., Cummins A.G., Keefe D.M. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J. Gastroenterol. Hepatol 2003, 18:1095-1100.
28. Crescenzi E., Chiaviello A., Canti G., Reddi E., Veneziani B.M., Palumbo G. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Mol. Cancer Ther 2006, 5:776-785.
29. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med 1997, 3:917-921.
30. Banerjee S., Wang Z., Kong D., Sarkar F.H. 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 2009, 69:5592-5600.
31. Fulda S., Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004, 64:337-346.
32. Li X., Zhu F., Jiang J., Sun C., Wang X., Shen M., et al. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells. Cancer Lett 2015, 357:219-230.
33. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 2002, 9:459-470.
34. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
35. Pop C., Salvesen G.S. Human caspases: activation, specificity, and regulation. J. Biol. Chem 2009, 284:21777-21781.
36. Cohen G.M. Caspases: the executioners of apoptosis. Biochem. J. 1997, 326(Pt 1):1-16.
37. Chipuk J.E., Moldoveanu T., Llambi F., Parsons M.J., Green D.R. The BCL-2 family reunion. Mol. Cell 2010, 37:299-310.
38. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001, 15:2922-2933.
39. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
40. Glienke W., Hausmann E., Bergmann L. Downregulation of STAT3 signaling induces apoptosis but also promotes anti-apoptotic gene expression in human pancreatic cancer cell lines. Tumor Biol 2011, 32:493-500.
41. Huang S., Chen M., Shen Y., Shen W., Guo H., Gao Q., et al. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett 2012, 315:198-205.
42. Gritsko T., Williams A., Turkson J., Kaneko S., Bowman T., Huang M., et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res 2006, 12:11-19.
43. Gangadharan C., Thoh M., Manna S.K. Inhibition of constitutive activity of nuclear transcription factor kappaB sensitizes doxorubicin-resistant cells to apoptosis. J. Cell. Biochem 2009, 107:203-213.
44. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5:297-309.
45. Liu P., Kimmoun E., Legrand A., Sauvanet A., Degott C., Lardeux B., et al. Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J. Hepatol 2002, 37:63-71.
46. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
47. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl Cancer Inst 1990, 82:4-6.
48. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
49. Rein D.T., Kurbacher C.M. The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects. Anticancer Drugs 2001, 12:787-795.